• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease.

作者信息

Dale Kelly, Fallouh Yasmeen, Alkhouri Naim

机构信息

Department of Hepatology, Arizona Liver Health, Chandler, AZ, USA.

出版信息

Expert Opin Investig Drugs. 2024 Nov;33(11):1095-1097. doi: 10.1080/13543784.2024.2401907. Epub 2024 Sep 10.

DOI:10.1080/13543784.2024.2401907
PMID:39256989
Abstract
摘要

相似文献

1
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease.代谢相关脂肪性肝病（MASLD）和代谢相关脂肪性肝炎（MASH）：命名的改变如何影响我们治疗肝病的方法。
Expert Opin Investig Drugs. 2024 Nov;33(11):1095-1097. doi: 10.1080/13543784.2024.2401907. Epub 2024 Sep 10.
2
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.低至中度饮酒与代谢功能障碍相关脂肪性肝病患者的纤维化增加有关。
J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4.
3
ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.谷丙转氨酶（ALT）水平、饮酒情况和代谢风险因素对普通人群的肝脏相关结局具有预后相关性。
JHEP Rep. 2024 Jul 24;6(10):101172. doi: 10.1016/j.jhepr.2024.101172. eCollection 2024 Oct.
4
Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.脂肪性肝病预测心血管疾病和晚期肝纤维化：一项具有 20 年随访的社区居民队列研究。
Metabolism. 2024 Apr;153:155800. doi: 10.1016/j.metabol.2024.155800. Epub 2024 Jan 22.
5
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.采用共识命名法的脂肪肝疾病及其分类的全国流行率估计。
Hepatology. 2024 Mar 1;79(3):666-673. doi: 10.1097/HEP.0000000000000604. Epub 2023 Sep 20.
6
Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.合并代谢相关脂肪性肝病、代谢相关酒精性肝病和酒精性肝病患者的特征及长期死亡率，以及SAFE评分的效用
JHEP Rep. 2024 Jun 3;6(10):101127. doi: 10.1016/j.jhepr.2024.101127. eCollection 2024 Oct.
7
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.脂肪性肝病：病理生理学与新兴药物治疗
Pharmacol Rev. 2024 May 2;76(3):454-499. doi: 10.1124/pharmrev.123.001087.
8
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
9
Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.代谢功能障碍相关脂肪性肝病（SLD）和酒精性肝病，但非无代谢功能障碍的SLD，在10年随访期内与慢性肾脏病的新发独立相关。
Hepatol Res. 2024 Aug 7. doi: 10.1111/hepr.14097.
10
Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.普通人群中风险 MASH、MetALD 和酒精相关脂肪性肝病的流行情况。
Aliment Pharmacol Ther. 2024 May;59(10):1271-1281. doi: 10.1111/apt.17958. Epub 2024 Mar 19.

引用本文的文献

1
Digital Pathology Tailored for Assessment of Liver Biopsies.专为肝活检评估量身定制的数字病理学
Biomedicines. 2025 Apr 1;13(4):846. doi: 10.3390/biomedicines13040846.